Polypeptides homologous to VEGF and BMP1

Details Polypeptides homologous to VEGF and BMP1 Polypeptides homologous to VEGF and BMP1

2004-06-04

2009-02-24

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S399000

Reexamination Certificate

active

07494977

ABSTRACT:
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4877864 (1989-10-01), Wang et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5106748 (1992-04-01), Wozney et al.
patent: 5166058 (1992-11-01), Wang et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5399677 (1995-03-01), Wolfman et al.
patent: 5453419 (1995-09-01), Murakami et al.
patent: 5543394 (1996-08-01), Wozney et al.
patent: 5620867 (1997-04-01), Kiefer et al.
patent: 5631142 (1997-05-01), Wang et al.
patent: 5637480 (1997-06-01), Celeste et al.
patent: 5641756 (1997-06-01), Robinson
patent: 5661007 (1997-08-01), Wozney et al.
patent: 5670338 (1997-09-01), Murakami et al.
patent: 6391311 (2002-05-01), Ferrara et al.
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 6620784 (2003-09-01), Ferrara et al.
patent: 6887982 (2005-05-01), Gao et al.
patent: 2003/0027998 (2003-02-01), Holtzman et al.
patent: 2003/0113870 (2003-06-01), Ferrara et al.
patent: 2004/0138417 (2004-07-01), Fitzpatrick et al.
patent: 2004/0219640 (2004-11-01), Ferrara et al.
patent: 2004/0235740 (2004-11-01), Ferrara et al.
patent: 2007/0031929 (2007-02-01), Ferrara
patent: 471754 (1996-07-01), None
patent: 370989 (1996-09-01), None
patent: WO 88/00205 (1988-01-01), None
patent: WO 94/01548 (1994-01-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 98/07832 (1998-02-01), None
patent: PCT/US98/06724 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 99/37671 (1999-07-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 99/47677 (1999-09-01), None
patent: WO 00/04183 (2000-01-01), None
patent: WO 00/18212 (2000-04-01), None
patent: WO 00/24774 (2000-05-01), None
patent: WO 00/32221 (2000-06-01), None
patent: WO 00/34474 (2000-06-01), None
patent: WO 00/37641 (2000-06-01), None
patent: WO 00/39284 (2000-07-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 00/59940 (2000-10-01), None
patent: WO 00/66736 (2000-11-01), None
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)”Proc. Natl. Acad. Sci. USA95(2) :548-553 (Jan. 20, 1998).
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”Arch. Ophthalmology114(1) :66-71 (1996).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other disorders”New England J. of Medicine331(22) :1480-1487 (1994).
Berkman et al., “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms”J. Clin. Invest.91(1) :153-159 (1993).
Borgstrom et al., “Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy”Cancer Research56(17) :4032-4039 (1996).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract”Cancer Research53(19) :4727-4735 (1993).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer”Human Pathology26(1) :86-91 (1995).
Burgess and Maciag, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins”Annu. Rev. Biochem.58:575-606 (1989).
Clapp et al., “The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis”Endocrinology133(3) :1292-1299 (1993).
Connolly et al., “Human Vascular Permeability Factor”Journal of Biological Chemistry264(33) :20017-20024 (1989).
Dvorak et al., “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis”American Journal of Pathology146(5):1029-1039 (1995).
Ferrara and Davis-Smyth., “The Biology of Vascular Endothelial Growth Factor.”Endocrine Reviews.18(1):4-25 (1997).
Ferrara and Henzel, “Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells”Biochem.&Biophys. Res. Comm.161(2):851-858 (1989).
Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins”Endo. Rev.13:18-32 (1992).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides”J. Cell. Biochem.47:211-218 (1991).
Folkman and Shing, “Angiogenesis”Journal of Biological Chemistry267:10931-10934 (1992).
Folkman et al., “Induction of angiogenesis during the transition from hyperplasia to neoplasia”Nature339(6219):58-61 (1989).
Good et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin”Proc. Natl. Acad. Sci. USA87(17):6624-6628 (1990).
Horak et al., “Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer”Lancet340(8828):1120-1124 (1992).
Houck et al., “The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA.”Mol. Endocrinol.5:1806-1814 (1991).
Ishikawa et al., “Identification of Angiogenic Activity and the Cloning and Expression of Platelet-Derived Endothelial Cell Growth Factor.”Nature.338:557-562 (1989).
Keck et al., “Vascular Permeability Factor, An Endothelial Cell Mitogen Related to PDGF”Science246:1309-1312 (1989).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo”Nature362:841-844 (1993).
Klagsbrun and D'Amore, “Regulators of angiogenesis”Ann. Rev. Physiol.53:217-239 (1991).
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”Science246:1306-1309 (1989).
Levine et al., “Bone morphogenetic protein promotes vascularization and osteoinduction in preformed hydroxyapatite in the rabbit”Annals of Plastic Surgery39(2):158-168 (Aug. 1997).
Lopez et al., “Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes”Invest. Ophthalmol. Vis. Sci.37(5):855-868 (1996).
Macchiarini et al., “Relation of neovascularisation to metastasis of non-small-cell lung cancer”Lancet340(8812):145-146 (1992).
Mattern et al., “Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma”Brit. J. Cancer73(7):931-934 (1996).
Melnyk et al., “Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth”Cancer Research56(4):921-924 (1996).
O'Reilly et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma”Cell79(2):315-328 (1994).
O'Reilly et al., “Endostatin: an endogenous inhibitor of angiogenesis and tumor growth”Cell88(2):277-285 (1997).
Takahara et al., “Bone morphogenetic protein-1 and a mammalian tolloid homologue (mTld) are enc

Affiliated with

Also associated with

Rating

Polypeptides homologous to VEGF and BMP1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polypeptides homologous to VEGF and BMP1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides homologous to VEGF and BMP1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4113518